MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Parkinson’s"

  • 2025 International Congress

    Dose Optimization of Foslevodopa/Foscarbidopa: Post Hoc Analysis of Study Completers

    J. Aldred, M. Bouchard, D. Kern, P. Mir, L. Bergmann, R. Gupta, M. O'Meara, J. Samuelsson, B. Bergmans (Spokane, USA)

    Objective: To describe dose optimization, efficacy, and safety of foslevodopa/foscarbidopa (LDp/CDp) in patients with advanced Parkinson’s disease (PwaPD) who completed a 52-week open-label study. Background:…
  • 2025 International Congress

    Effect of Opicapone on Sleep-Related Complaints and Non-Motor Burden in Parkinson’s Patients: A Post-Hoc Analysis of the OASIS Trial

    J. Ferreira, M. Gago, R. Costa, M. Fonseca, H. Brigas, D. Martins, J. Holenz, C. Trenkwalder (Lisbon, Portugal)

    Objective: To assess the effect of opicapone (OPC) on different sleep complaints and non-motor symptoms (NMS) in fluctuating Parkinson’s disease (PD) patients with sleep disturbances.…
  • 2025 International Congress

    Unilateral focused ultrasound subthalamotomy in early Parkinson’s disease: randomized-controlled trial protocol

    R. Martinez-Fernandez, MC. Rodriguez Oroz, S. Paschen, C. Juri, M. Del Alamo, E. Natera-Villalba, R. Rodriguez-Rojas, LH. Gonzalez-Quarante, M. Synowitz, J. Lorenzoni, CA. Sánchez-Catasús, S. Obika, T. Jimenez-Castellanos, P. Reiters, E. Cerutti, RA. Villino-Boquete, C. Ferrer, O. Rascol, G. Deuschl, JA. Obeso (Madrid, Spain)

    Objective: To describe the protocol of a multicenter, prospective, randomized controlled trial (EarlyFocus II) which evaluates the efficacy and safety of unilateral magnetic resonance-guided focused…
  • 2025 International Congress

    Harnessing Digital Biomarkers to Monitor Early Parkinson’s Disease Progression

    V. Shah, C. Silva-Batista, D. Engel, A. Ragothaman, P. Burgos, P. Carlson-Kuhta, F. Horak, M. Mancini (Philadelphia, USA)

    Objective: This study aimed to identify gait metrics capable of capturing disease progression in individuals with early Parkinson’s disease (PD). Background: Digital gait assessments have…
  • 2025 International Congress

    Efficacy and Safety of IPX203 and Levodopa-Carbidopa Intestinal Gel (LCIG) Compared to Immediate-Release Carbidopa-Levodopa in Parkinson’s Disease: A Systematic Review and Meta-Analysis

    M. Mustafa, A. Abunamoos, Y. Aljazi, F. Alnajjar, A. Sa’D, M. Alghaniem, K. Abuhananeh (Amman, Jordan)

    Objective: To conduct the efficacy and safety of IPX203, an extended-release carbidopa-levodopa formulation, and LCIG, a continuous levodopa infusion, compared to Immediate-Release Carbidopa-Levodopa (IR CD-LD)…
  • 2025 International Congress

    Solengepras: An Investigational Therapy with Potential Benefits on Functional and Non-Motor Measures in Parkinson’s Disease (PD)

    S. Isaacson, K. Chou, H. Sarva, S. Merchant, C. Scholl, M. Charles, N. Brice, L. Dawson, M. Carlton, S. Vaidya, K. Kieburtz, R. Hauser, A. Ellenbogen (Ann Arbor, USA)

    Objective: Solengepras is a GPR6-inhibitor that is being studied as an investigational treatment for Parkinson’s Disease (PD). Background: GPR6 is a novel G-protein-coupled receptor found…
  • 2025 International Congress

    Advancements in Microbiome Research: Total Microbial Load, Differential Absolute Abundance, and Correlations with Immune Transcriptomics

    B. Palushaj, M. Chakraborty, I. Porter, G. Reynolds, E. Brooks, Z. He, A. Bhatt, K. Poston (Palo Alto, USA)

    Objective: Quantify total microbial load in the gut microbiome of people with Parkinson’s disease (PD) and compare the absolute abundance of bacterial taxa between PD…
  • 2025 International Congress

    A novel virtual home-safety fall prevention program for Parkinson’s Disease

    M. Afshari, V. Palakuzhy, G. Jones, A. Hernandez, B. Ouyang, C. Goetz (Chicago, USA)

    Objective: To determine the feasibility and preliminary efficacy of a novel virtually-delivered protocol targeting extrinsic environmental fall risk factors in the homes of persons with…
  • 2025 International Congress

    Istradefylline for Freezing of Gait in Parkinson’s Disease: A Systematic Review and Meta-Analysis

    A. Fornari Caprara, J. Pitton Rissardo (Camden, USA)

    Objective: To evaluate the effects of istradefylline on motor function and freezing of gait (FOG) in patients with Parkinson’s disease (PD). Background: FOG is a…
  • 2025 International Congress

    Risk factors for central nervous system side effects of amantadine

    M. Nagai, N. Miyaue, Y. Ito, Y. Yamanishi, R. Ando, Y. Ihara (Ehime, Japan)

    Objective: The purpose of this study was to investigate the threshold blood level of amantadine and risk factors for central nervous system (CNS) side effects…
  • « Previous Page
  • 1
  • …
  • 92
  • 93
  • 94
  • 95
  • 96
  • …
  • 436
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • “Magic carpet for freezing of gait ” Evaluating a combination of patterned and pictographic visual cues.
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley